In a clinical trial, a pharmaceutical cocktail containing anti-TIGIT (Etigilimab) and an anti-PD-1 (Nivolumab) antibody was used to eradicate cancer and restore immune response, and the results of this trial showed the tolerability of therapy [168]. Here, PDCD1 is linked to cancer.